ACTION OF SOLIAN TREATMENT ON NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA
Objectives: to evaluate the efficacy and tolerability of Solian (amisulpride) in remission phase in patients with predominance of negative symptoms of schizophrenia. Material and methods: 327 patients with prevalence of negative symptoms of schizophrenia aged 18 to 65 years were included in this multicentre, open, uncontrolled study. Solian was recommended in doses from 50 to 300 mg/day for 9 months. Overall efficacy of therapy was assessed by Clinical Global Impression Scale (CGI). The severity of negative symptoms was assessed by PANSS sub-scale of negative symptoms. Results: At the beginning of the study 32 (9.8%) patients were «severely 105 (32.1%) were "markedly ill" and 144 (44%) were "moderately ill". At the endpoint of the study improvement was observed in 307 (93.9%) patients: 103 patients (31.5%) had «very much improvement», 149 patients (45.6%) had «much improvement» and 55 patients (16.8%) had «minimal improvement». The average total score of PANSS negative symptoms was reduced by 52.2% (p<0.001) from baseline to the last visit (29.4±6.6). Solian didn't affect the basic vital signs such as heart rate, blood pressure and weight. 83 (25.4%) patients experienced at least one adverse event. Sleep disturbance, drowsiness and dry mouth were the most common adverse events. 42 (12.8%) patients were prematurely withdrawn from the study including 2 (0.6%) patients withdrawn due to adverse events (one patient developed galactorrhea, another one had persistent insomnia and tardiness).